Skip to main content

This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

  1. Article
  2. Source: Campus Sanofi
  3. 23 Jul 2025

Therapeutic indications for Praluent® (alirocumab)

Author: Sanofi

Editorial Team

                     
Praluent logo

Prescribing Information (UK)

Primary hypercholesterolaemia and mixed dyslipidaemia1

  • PRALUENT® is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:
    • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
    • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant or for whom a statin is contraindicated

Established atherosclerotic cardiovascular disease1

  • PRALUENT® is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels as an adjunct to correction of other risk factors:

    • in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies, or

    • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant or for whom a statin is contraindicated

SEE MORE FROM SCIENCE

Praluent®

Find more information on Indication, Administration and Mechanism of Action and watch videos about Praluent®.

Patient Website

Find resources and support for your patients on Praluent®. Find useful links about how patients can manage their cholesterol.

Get in touch with the Dyslipidaemia Team
MAT-XU-2201545 (v5.0) Date of Preparation: October 2023
References
  1. Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/8093/smpc. Accessed July 2025.

MAT-XU-2503036 (v1.0) Date of Preparation: July 2025  

Related Content